(BFM Stock Exchange) – The specialist in infectious disease vaccines has unveiled promising intermediate clinical results for its VLA15 vaccine candidate against Lyme disease.

Valneva experienced an eventful August on August on the Paris Stock Exchange. The action of the specialist in vaccines for infectious diseases collapsed by 22.18% on August 25, weighed down by the sales suspension of his chikungunya vaccine in the United States, after four cases of serious undesirable effects.

This time, Valneva announces good news concerning one of its vaccines under development. The group specializing in infectious disease vaccines has published new encouraging new data for VLA-15, its candidate Vaccine against Lyme, developed in collaboration with Pfizer on Wednesday.

Caused by tick stings, this disease can cause joint, nervous or skin complications if it is not treated in the primary stage. There is currently no human vaccine against this disease.

A strong immune response

The data published by Valneva, resulting from phase II, that is to say at an intermediate stage which aims to demonstrate the effectiveness of a treatment, thus showed a strong anamnestic response (immune memory), one month after the administration of a third dose of reminder of VLA15 to 42nd month in children aged 5 to 11 years), adolescents (aged 12 to 17) as well as adults ( 65 years).

“The strong immune response and the favorable safety profile observed after receiving this third dose of recall were similar to those reported after receiving the previous doses of recall thus demonstrating the potential benefit that a recall vaccination could have before each season of Lyme disease,” said Valneva.

On the Paris Stock Exchange, Action Valneva increased after the announcement of its results, winning 8.5% shortly before 3 p.m.

Phase III results at the end of the year

The publication of the results of the phase III clinical trial (last step before a potential marketing) evaluating the VLA15 vaccine of Valneva against Lyme disease is expected after the end of October. The objective being that the American giant submits a request for marketing authorization (BLA) to the American health agency FDA and a request for marketing authorization (AMM) at the European Medicines Agency in 2026, provided that the data obtained is positive.

“If the vaccine is approved and marketed, Valneva could receive from Pfizer up to $ 143 million in payments linked to the first stages of product marketing, sales royalties ranging from 14% to 22% as well as step -based sales payments that can reach $ 100 million,” said the company in a previous communication.

The group also confirmed in mid-August that the phase I results, a phase which assesses the safety of employment of a treatment, of its candidate-vaccin against the Zika virus were expected this year. The group also has two phase II trials (a step which assesses the efficiency and tolerance of a treatment) which currently evaluate a candidate-vaccine against shigellosis, an acute infectious diarrhea.